Figure 7.

The LCK inhibitor (CAS) attenuated downstream phosphorylation in pZAP70. B cells were treated with VH (0.02% DMSO) or TCDD (10 nM) and activated by soluble human recombinant CD40 ligand and cytokines (IL-2 and IL-21) for 7 days. All samples were measured by flow cytometry. (A) Percent pLCK-Tyr505 positive; (B) levels of pLCK-Tyr505⁺ B cells with or without the addition of LCK inhibitor (CAS 213743-31-8). Significant differences from VH control are indicated by * p<0.05 by 1-way ANOVA followed by Fisher’s LSD post hoc test. Results are presented as the normalized percentage compared to the VH group. “N” indicates the number of donors used in the study.